HPV 16/18 Screening: Antigen Tests for Cervical Cancer Programs

Why HPV 16 and 18 are the priority genotypes

Of the more than 200 HPV genotypes that have been identified, roughly 12 are classified as high-risk or oncogenic for cervical cancer. The two with the highest oncogenic potential are HPV 16 and HPV 18. Together they account for approximately 70 percent of cervical cancer cases worldwide, with HPV 16 alone responsible for roughly half of all cervical cancers and HPV 18 for another 15 to 20 percent.

This concentration of risk in two genotypes is the foundation of HPV 16/18 testing as a screening strategy. A test that identifies HPV 16 or HPV 18 at a screening visit is identifying the women at the highest immediate risk of high-grade cervical intraepithelial neoplasia (CIN2+) and of progression to invasive cervical cancer. The remaining cervical cancer burden is distributed across HPV 31, 33, 45, 52, and 58 (the next five highest-risk genotypes), with smaller contributions from other oncogenic types.

The clinical implication is that a screening program which correctly identifies HPV 16/18 infections and routes those women to colposcopy or close-interval follow-up is intercepting the majority of the cervical cancer risk. This is why HPV 16/18 genotyping is one of the accepted reflex pathways in the WHO cervical cancer screening algorithm, alongside primary HPV DNA testing for any high-risk genotype and visual inspection with acetic acid in resource-limited settings.

Where HPV antigen tests fit alongside DNA testing

The screening landscape uses several HPV detection technologies, and the right one depends on the local laboratory capacity, the budget, the screening algorithm, and the patient pathway.

HPV DNA testing is the gold standard for primary screening under the WHO 2021 recommendations, and remains the default where laboratory infrastructure, sample transport, and budget allow. HPV antigen testing occupies three distinct roles: as an adjunct to confirm a positive DNA result in a triage pathway, as a primary screen in settings where DNA testing is not yet feasible, and as a community-level point-of-care test where laboratory turnaround is impractical.

The procurement officer’s job is to match the test to the algorithm. A program that uses HPV DNA testing as the primary screen may still use HPV antigen testing for community-level outreach or for triage in a specific sub-population. A program in a low-resource setting without DNA infrastructure may use HPV antigen testing as the primary screen with VIA as the triage step. The choice is governed by the local algorithm and the available laboratory capacity, not by the test manufacturer’s preference.

The WHO 90-70-90 cervical cancer elimination strategy

In November 2020, the World Health Assembly adopted the global strategy to accelerate the elimination of cervical cancer as a public health problem. The strategy is built around three numerical targets to be reached by 2030:

• 90 percent of girls fully vaccinated with the HPV vaccine by age 15
• 70 percent of women screened with a high-performance test by age 35 and again by age 45
• 90 percent of women identified with cervical disease receiving treatment

The screening target is the one most directly relevant to HPV 16/18 antigen test procurement. The WHO recommends HPV DNA testing as the primary screening method, with HPV self-sampling as a key strategy to reach under-screened populations. HPV antigen testing is recognized in the WHO guidance as an option in resource-limited settings where DNA infrastructure is not available, and is also used as a triage adjunct where the local algorithm calls for it.

The 90-70-90 framework has driven national cervical cancer elimination plans in dozens of countries since 2020, including the United States, the United Kingdom, the European Union, China, India, and the African Union member states. Each national plan translates the WHO targets into local action, and procurement officers at the country and program level are designing screening programs against these targets.

The 2024-2026 U.S. and EU policy updates

Three specific policy developments in 2024 have reshaped the screening landscape and are worth procurement officers’ attention:

U.S. Preventive Services Task Force 2024 recommendation update. The USPSTF updated its cervical cancer screening recommendation in 2024 to support self-collection of HPV samples as an alternative to clinician-collected samples for women aged 30 to 65 undergoing cervical cancer screening. The update formally recognises that self-collected HPV samples, when processed by a high-performance HPV DNA test, perform comparably to clinician-collected samples for the screening endpoint. Self-collection is one of the most important operational changes in the U.S. screening landscape in the past five years.

U.S. FDA approval of HPV self-collection device. In 2024, the FDA approved the first HPV self-collection device for cervical cancer screening in the United States, enabling women to collect their own sample at home or in a community clinic without a speculum exam. The approval follows years of validation studies and represents the regulatory framework shift needed for self-collection to become a routine part of U.S. screening practice.

European Union IVDR full application. The EU In Vitro Diagnostic Medical Devices Regulation (IVDR, EU 2017/746) entered full application on 26 May 2022, with a transition period that has now substantially closed for new product placements. Compared to the legacy IVDD, IVDR raises the clinical-evidence bar for IVDs substantially, with most HPV tests now requiring conformity assessment by a notified body rather than self-declaration. Procurement officers sourcing HPV tests for the EU should confirm the supplier’s IVDR certificate and the date of CE marking under IVDR, not the legacy IVDD.

These three updates together mean that the procurement specification for an HPV test in 2026 is meaningfully different from the 2020 specification: self-collection support, IVDR CE marking, and validated performance against the CIN2+ endpoint are now baseline requirements for most procurement bodies.

Standards and authoritative references

For procurement officers building an HPV 16/18 antigen test specification, the authoritative references are:

• WHO Cervical Cancer fact sheet — the WHO’s reference overview of cervical cancer, the HPV link, screening guidelines, and the 90-70-90 elimination targets. Updated as new guidelines are published.
• IARC (International Agency for Research on Cancer) cervical cancer monograph — the IARC monograph on cervical cancer provides the epidemiological and biological evidence base for the screening recommendations.
• USPSTF cervical cancer screening recommendation — the U.S. Preventive Services Task Force recommendation, including the 2024 update supporting self-collected HPV samples.
• NCI (US National Cancer Institute) cervical cancer page — the U.S. National Cancer Institute reference on cervical cancer types, prevention, screening, and treatment.
• U.S. CDC cervical cancer page — the U.S. Centers for Disease Control and Prevention program reference for HPV vaccination, screening, and follow-up.

Procurement officers should also reference the destination market’s local public health authority — the National Health Commission of the People’s Republic of China, the European Centre for Disease Prevention and Control, the African CDC, or the equivalent national body — for the locally applicable screening algorithm.

Performance characteristics to require in the validation dossier

For an HPV 16/18 antigen test in a screening program, the validation dossier should include four elements. The first three are the clinical performance numbers; the fourth is the operational reproducibility data.

Clinical sensitivity for the CIN2+ endpoint

Sensitivity for high-grade cervical intraepithelial neoplasia (CIN2+) is the operationally meaningful metric for a screening test, because it captures the cases the screening is supposed to detect. The validation should report sensitivity against a reference standard (typically HPV DNA testing with genotyping confirmation, or histology for biopsy-confirmed disease). The dossier should report sensitivity in the relevant population (women aged 30-65 in primary screening, or the local algorithm’s target age band).

Clinical specificity for the CIN2+ endpoint

Specificity is what determines the false-positive rate at population scale. A test with 95% specificity generates five false positives per hundred screened; a test with 98% specificity generates two. At population scale, the difference multiplies into meaningful numbers of unnecessary colposcopies and biopsies.

Cross-reactivity profile

The validation should report cross-reactivity against non-target HPV genotypes (HPV 6, 11, 31, 33, 45, 52, 58 and others) and against non-HPV organisms likely to be present in cervical samples. A HPV 16/18 antigen test that cross-reacts with HPV 6 or 11 (which are genital wart genotypes, not oncogenic) is producing false positives that compromise the screening program.

Lot-to-lot reproducibility

Screening programs run large volumes over multi-year periods and depend on consistent performance across manufacturing lots. The dossier should report inter-lot, inter-operator, and inter-site reproducibility data over at least three independent lots.

Testsealabs’ HPV antigen tests for 16/18 detection carry clinical validation against the CIN2+ endpoint, with high sensitivity and high specificity, and are validated against non-target HPV genotypes. The validation dossier is available on request through the Testsealabs project team.

Regulatory pathway for the destination market

The required approvals depend on the destination market:

Testsealabs’ IVD portfolio is manufactured under the company’s IVD quality system at the Hangzhou facility. The validation dossiers and regulatory certificates are available on request through the Testsealabs project team contact page.

Commercial specification: MOQ, storage, shelf life, OEM

For procurement officers building the commercial specification, the typical operational parameters for an HPV 16/18 antigen test program are:

• Storage condition: 4-30 °C. This is the standard room-temperature range that allows the kit to be shipped and stored without a cold chain, which matters for community clinics and last-mile logistics in low-resource settings.
• Shelf life: 24 months from date of manufacture. This window allows the kit to clear customs, sit in regional warehouses, and reach the end clinic with enough remaining shelf life for the screening program to use it.
• Minimum order quantity (MOQ) for catalog stock: 5,000 units. This is the minimum that makes the production scheduling and packaging economics work for an IVD rapid test.
• Minimum order quantity (MOQ) for OEM private-label customization: 50,000 units. This threshold covers the artwork setup, the language customization on the packaging, and the kit component sourcing specific to the OEM customer.
• Performance characteristics: high sensitivity, high specificity, validated against the CIN2+ endpoint with cross-reactivity characterization against non-target HPV genotypes.

These parameters are standard for the IVD rapid test category and should be the baseline of the procurement specification. Programs with unusual logistics constraints (e.g., extreme climates, very long distribution chains) should negotiate the storage condition and shelf life specifically, since the standard 4-30 °C / 24-month envelope assumes moderate conditions.

Implementation in a screening program

For a procurement officer who has selected an HPV 16/18 antigen test and is now designing the screening program implementation, four operational elements matter:

1. Sample collection pathway. Clinician-collected cervical sample, self-collected vaginal sample, or both? The 2024 USPSTF self-collection update makes the self-collection option standard for U.S. programs, and the WHO guidance makes it a priority for under-screened populations in LMIC programs.
2. Laboratory workflow. Where will the test be run? On-site at the clinic, at a regional lab, or at a central reference lab? Antigen tests are typically point-of-care or near-patient; DNA tests require a laboratory with PCR or hybrid capture instrumentation.
3. Triage algorithm. A positive HPV 16/18 antigen test result triggers what? Colposcopy referral, HPV DNA confirmation, or VIA triage? The local algorithm determines the next step, and the test is positioned within that algorithm.
4. Quality monitoring. How will the program monitor test performance against the reference standard in routine use? WHO Prequalification and CE-IVDR programs require post-market surveillance; the program should have its own quality agreement with the manufacturer.

Testsealabs supports each of these operational elements through its distribution partner network, including operator training materials, validation dossiers, and post-market surveillance reporting templates.

HPV self-sampling and the antigen test pathway

HPV self-sampling — where a woman collects her own vaginal or cervical-vaginal sample using a kit at home or in a community clinic, then sends the sample to a laboratory — is one of the most important operational changes in cervical cancer screening in the past decade. Self-sampling is the recommended strategy for reaching women who are under-screened, including women in low-resource settings, women in remote or rural areas, and women who are reluctant to undergo a speculum examination.

The 2024 USPSTF recommendation update and the 2024 FDA self-collection device approval make self-sampling a routine part of the U.S. screening landscape. The WHO has recommended self-sampling for under-screened populations since 2021.

For procurement officers designing a self-sampling program, the test format matters. DNA tests are the gold standard for the self-collected sample analysis. HPV antigen tests are typically designed for clinician-collected cervical samples rather than self-collected vaginal samples. For programs that combine self-sampling with antigen testing, the test format and the self-collection device need to be validated together.

A short summary for the procurement officer

If you are sourcing HPV 16/18 antigen tests for a cervical cancer screening program in 2026, the procurement specification has five anchor points: the local screening algorithm that defines where the antigen test fits in the cascade; the destination-market regulatory approval (FDA, CE-IVDR, NMPA, WHO PQ); the clinical validation dossier with sensitivity, specificity, cross-reactivity, and lot-to-lot reproducibility; the operational specification (4-30 °C storage, 24-month shelf life, MOQ 5,000 catalog or 50,000 OEM); and the post-market quality agreement that supports the screening program over the multi-year horizon.

Testsealabs’ HPV test series supports each of these anchor points. The Testsealabs HPV test product range covers the formats that procurement officers typically request, including the antigen-based 16/18 screening format discussed in this article. The Testsealabs HPV test midstream product page covers the technical and packaging specifications. For quotation and sample requests, the Testsealabs project team contact page is the right escalation; our team returns a quotation, a validation dossier summary, and a sample within five business days.

Frequently asked questions

Why do HPV 16 and 18 matter for cervical cancer screening?

HPV 16 and HPV 18 together account for approximately 70 percent of cervical cancer cases worldwide. A test that reliably identifies these two genotypes at a screening visit identifies the women at the highest immediate risk of CIN2+ and invasive cervical cancer.

Is HPV antigen testing the same as HPV DNA testing?

No. HPV antigen tests detect HPV capsid proteins; HPV DNA tests detect viral DNA. HPV DNA testing is the WHO-preferred primary screening method. HPV antigen testing is an adjunct, a triage step, or a primary screen in resource-limited settings.

What is the WHO 90-70-90 cervical cancer elimination target?

The 2020 WHO strategy targets by 2030: 90% of girls vaccinated against HPV by age 15; 70% of women screened with a high-performance test by ages 35 and 45; 90% of women identified with cervical disease receiving treatment.

How does HPV self-sampling fit into the screening algorithm?

HPV self-sampling is recommended by the WHO for under-screened populations (2021) and supported by the U.S. Preventive Services Task Force (2024 update) as an alternative to clinician-collected samples. The FDA approved the first HPV self-collection device in 2024.

What performance characteristics should procurement officers look for in an HPV antigen test?

Clinical sensitivity and specificity for the CIN2+ endpoint against a reference standard, cross-reactivity against non-target HPV genotypes, and lot-to-lot reproducibility over multiple manufacturing lots.

What regulatory approvals should an HPV screening test carry?

FDA for the US, CE-IVDR (EU 2017/746) for the EU, NMPA for China, PMDA for Japan, TGA for Australia, and WHO Prequalification for UN agency procurement. The exact pathway depends on the destination market.

How are HPV antigen tests used in national cervical cancer screening programs?

Where HPV DNA testing is available at scale, antigen tests are typically used as triage or adjunct. Where DNA infrastructure is not yet available, antigen tests may be used as the primary screen with VIA as triage. The choice depends on the local algorithm and laboratory capacity.